BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 16813162)

  • 1. [RET and GFRA1 germline polymorphisms in medullary thyroid cancer patients].
    Severskaia NV; Saenko VA; Il'in AA; Chebotareva IV; Rumiantsev PO; Isaev PA; Medvedev VS; Iasmita S
    Mol Biol (Mosk); 2006; 40(3):425-35. PubMed ID: 16813162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The RET polymorphic allele S836S is associated with early metastatic disease in patients with hereditary or sporadic medullary thyroid carcinoma.
    Siqueira DR; Romitti M; da Rocha AP; Ceolin L; Meotti C; Estivalet A; Puñales MK; Maia AL
    Endocr Relat Cancer; 2010 Dec; 17(4):953-63. PubMed ID: 20801952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical relevance of RET variants G691S, L769L, S836S and S904S to sporadic medullary thyroid cancer.
    Machens A; Frank-Raue K; Lorenz K; Rondot S; Raue F; Dralle H
    Clin Endocrinol (Oxf); 2012 May; 76(5):691-7. PubMed ID: 22111543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [G691S, L769L and S836S ret proto-oncogene polymorphisms are not associated with higher risk to sporadic medullary thyroid carcinoma in Chilean patients].
    Wohllk G N; Soto C E; Bravo A M; Becker C P
    Rev Med Chil; 2005 Apr; 133(4):397-402. PubMed ID: 15953945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms in exon 13 and intron 14 of the RET protooncogene: genetic modifiers of medullary thyroid carcinoma?
    Baumgartner-Parzer SM; Lang R; Wagner L; Heinze G; Niederle B; Kaserer K; Waldhäusl W; Vierhapper H
    J Clin Endocrinol Metab; 2005 Nov; 90(11):6232-6. PubMed ID: 16118333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population.
    Elisei R; Cosci B; Romei C; Bottici V; Sculli M; Lari R; Barale R; Pacini F; Pinchera A
    J Clin Endocrinol Metab; 2004 Jul; 89(7):3579-84. PubMed ID: 15240649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additive effect of RET polymorphisms on sporadic medullary thyroid carcinoma susceptibility and tumor aggressiveness.
    Ceolin L; Siqueira DR; Ferreira CV; Romitti M; Maia SC; Leiria L; Crispim D; Ashton-Prolla P; Maia AL
    Eur J Endocrinol; 2012 May; 166(5):847-54. PubMed ID: 22345297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RET polymorphisms in codons 769 and 836 are not associated with predisposition to medullary thyroid carcinoma.
    Wiench M; Włoch J; Wygoda Z; Gubała E; Oczko M; Pawlaczek A; Kula D; Lange D; Jarzab B
    Cancer Detect Prev; 2004; 28(4):231-6. PubMed ID: 15350625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of the RET proto-oncogene polymorphisms in Turkish sporadic medullary thyroid carcinoma patients.
    Gursoy A; Erdogan MF; Erdogan G
    J Endocrinol Invest; 2006 Nov; 29(10):858-62. PubMed ID: 17185892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germline sequence variant S836S in the RET proto-oncogene is associated with low level predisposition to sporadic medullary thyroid carcinoma in the Spanish population.
    Ruiz A; Antiñolo G; Fernández RM; Eng C; Marcos I; Borrego S
    Clin Endocrinol (Oxf); 2001 Sep; 55(3):399-402. PubMed ID: 11589684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
    Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative assessment of the association between L769L and S836S polymorphisms at RET gene and medullary thyroid carcinoma risk.
    Zhang Y; Wang S; Chen X; Huang S; Li J
    Tumour Biol; 2014 Jul; 35(7):6641-7. PubMed ID: 24699996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphisms in the RET proto-oncogene and the phenotypic presentation of familial medullary thyroid carcinoma.
    Magalhães PK; de Castro M; Elias LL; Soares EG; Maciel LM
    Thyroid; 2004 Oct; 14(10):848-52. PubMed ID: 15588382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The frequency of selected polymorphic variants of the RET gene in patients with medullary thyroid carcinoma and in the general population of central Poland.
    Sromek M; Czetwertyńska M; Skasko E; Zielińska J; Czapczak D; Steffen J
    Endocr Pathol; 2010 Sep; 21(3):178-85. PubMed ID: 20521125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Genetic polymorphisms: implications in the pathogenesis of medullary thyroid carcinoma].
    Rocha AP; Magalhães PK; Maia AL; Maciel LM
    Arq Bras Endocrinol Metabol; 2007 Jul; 51(5):723-30. PubMed ID: 17891235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possible Impact of RET Polymorphism and Its Haplotypic Association Modulates the Susceptibility to Thyroid Cancer.
    Khan MS; Pandith AA; Iqbal M; Naykoo NA; Khan SH; Rather TA; Mudassar S
    J Cell Biochem; 2015 Aug; 116(8):1712-8. PubMed ID: 25736215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of medullary thyroid carcinoma.
    Jiménez C; Hu MI; Gagel RF
    Endocrinol Metab Clin North Am; 2008 Jun; 37(2):481-96, x-xi. PubMed ID: 18502338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RET genotypes in sporadic medullary thyroid cancer: studies in a large Italian series.
    Fugazzola L; Muzza M; Mian C; Cordella D; Barollo S; Alberti L; Cirello V; Dazzi D; Girelli ME; Opocher G; Beck-Peccoz P; Persani L
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):418-25. PubMed ID: 18284634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single nucleotide polymorphisms act as modifiers and correlate with the development of medullary and simultaneous medullary/papillary thyroid carcinomas in 2 large, non-related families with the RET V804M proto-oncogene mutation.
    Shifrin AL; Ogilvie JB; Stang MT; Fay AM; Kuo YH; Matulewicz T; Xenachis CZ; Vernick JJ
    Surgery; 2010 Dec; 148(6):1274-80; discussion 1280-1. PubMed ID: 21134561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphisms in the initiators of RET (rearranged during transfection) signaling pathway and susceptibility to sporadic medullary thyroid carcinoma.
    Cebrian A; Lesueur F; Martin S; Leyland J; Ahmed S; Luccarini C; Smith PL; Luben R; Whittaker J; Pharoah PD; Dunning AM; Ponder BA
    J Clin Endocrinol Metab; 2005 Nov; 90(11):6268-74. PubMed ID: 16091499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.